About mirvetuxim ab soravtansi
Folate receptor alpha-targeted antibody-drug conjugate
Used for
- Treats folate receptor alpha-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after prior treatments.
Usual adult dose
6 mg/kg adjusted ideal body weight by intravenous infusion every 3 weeks; specialist-supervised treatment.
Common side effects
- Vision changes, including blurred vision and dry eyes
- Nausea, diarrhea, and abdominal pain
- Fatigue and reduced appetite
- Peripheral neuropathy
Important warnings
- Eye problems can be serious; eye examinations and preventive eye medicines are required.
- Infusion reactions and lung inflammation can occur.
- May cause harm to an unborn baby; pregnancy testing and contraception are required.
- Avoid contact lenses during treatment unless directed by an eye-care professional.
Pregnancy
May harm an unborn baby. Not recommended during pregnancy; effective contraception is advised during treatment and for 7 months afterward.
Breastfeeding
Do not breastfeed during treatment and for 1 month after the final dose.
Interactions
- Strong CYP3A4 inhibitors may increase exposure; examples include clarithromycin and ketoconazole.
- Strong CYP3A4 inducers may decrease exposure; examples include rifampin and carbamazepine.
- Tell the cancer team about all medicines and supplements before treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.